RxDoctor Payments Data

Anagha Agarwal, MD

Internal Medicine · Frisco, TXNPI 1295946648

Payments from drug & device makers

$1,194in general payments, 2019–2025

Across 39 payments — averaging $30.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$330
  • Abbott$236
  • Exact Sciences$127
  • Lilly USA, LLC$102
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$98
  • Medtronic$46
  • plus $254 from 10 others

What the payments were for

  • Food & beverage$1,194100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,194 in reported general payments places this provider in the 70th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$105,270
Medicare patients
115
Services billed
1,857

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide22$55,023
JardianceEmpagliflozin22$30,243
EliquisApixaban27$24,845
MounjaroTirzepatide12$24,307
JanuviaSitagliptin Phosphate16$22,181
FarxigaDapagliflozin Propanediol16$21,800
Levothyroxine Sodium170$1,655
Atorvastatin Calcium177$989
Fluticasone-SalmeterolFluticasone Propion/Salmeterol11$893
SynthroidLevothyroxine Sodium18$891
Losartan Potassium90$826
Rosuvastatin Calcium60$684
Omeprazole51$574
Amlodipine Besylate119$554
Albuterol Sulfate HfaAlbuterol Sulfate19$539

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$330$55,02322 claims
Boehringer IngelheimJardiance$17$30,24322 claims
PfizerEliquis$36$24,84527 claims
Lilly USA, LLCMounjaro$102$24,30712 claims
AstraZenecaFarxiga$46$21,80016 claims
ANI Pharmaceuticals, Inc.Valsartan$24$19811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Frisco

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →